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Abstract 
With the advancement of personalized cancer immunotherapies, new tools are needed to identify 
tumor antigens and evaluate T-cell responses in model systems, specifically those that exhibit 
clinically relevant tumor progression.  Key transgenic mouse models of breast cancer are 
generated and maintained on the FVB genetic background, and one such model is the mouse 
mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT) mouse – an 
immunocompetent transgenic mouse that exhibits spontaneous mammary tumor development 
and metastasis with high penetrance. Backcrossing the MMTV-PyMT mouse from the FVB 
strain onto a C57BL/6 genetic background, in order to leverage well-developed C57BL/6 
immunological tools, results in delayed tumor development and variable metastatic phenotypes.  
Therefore, we initiated characterization of the FVB MHC class I H-2
q 
haplotype to establish 
useful immunological tools for evaluating antigen specificity in the murine FVB strain.  Our 
study provides the first detailed molecular and immunoproteomic characterization of the FVB H-
2
q
 MHC class I alleles, including >8500 unique peptide ligands, a multi-allele murine MHC 
peptide prediction tool, and in vivo validation of these data using MMTV-PyMT primary tumors. 
This work allows researchers to rapidly predict H-2 peptide ligands for immune testing, 
including, but not limited to, the MMTV-PyMT model for metastatic breast cancer. 
  
on April 19, 2018. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 3, 2018; DOI: 10.1158/2326-6066.CIR-17-0298 
 3 
Introduction 
The success of cancer immunotherapies has shed considerable light on the ability of the host 
immune system to survey and eliminate aberrant tumor cells.  Pivotal to such therapies is the 
ability of the immune system to specifically recognize the tumor, a process that occurs at the 
immunological synapse when the T-cell receptor (TCR) of cytotoxic T lymphocytes (CTLs) 
binds to tumor-specific intracellular peptides presented by major histocompatibility complex 
(MHC) class I molecules. Such peptides can be derived from pathogen, host, or mutated-self 
proteins, the latter being classified as tumor neoantigens. Recognition of these peptide-MHC 
(pMHC) complexes by TCRs is a prerequisite for T-cell activation and tumor cell elimination.  
This mechanism is so critical to anti-tumor immunity that successful CTL responses against 
tumor neoantigens can induce long-term remission in a subset of patients with melanoma [1, 2].  
Unfortunately, many cancers, including breast cancers, have low mutation burdens and/or “cold” 
immunologic microenvironments and, so far, have responded poorly to immunotherapy [3]. 
Thus, advanced tools, such as immune-competent mouse models of breast cancer, are needed for 
studying how antigen-specific CTL responses are regulated in breast and other cancers.              
 
The mouse mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT) transgenic 
mouse is widely used for studying breast cancer because tumors arise with high penetrance, 
spontaneously metastasize to the lungs, and exhibit clinically relevant histology in the FVB/NJ 
background [4].  Other  well-established breast cancer models (MMTV-Neu, MMTV-c-Myc, 
MMTV-Wnt1) are also found in the FVB strain, in large part due to the technical feasibility of 
introducing transgenes into this strain [5].  Given the centrality of the FVB mouse to in vivo 
breast cancer studies, the ability to track antigen-specific T-cell responses would be 
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transformative to the utility of these murine models.   Here we address this issue by combining 
proteomics and in silico MHC immunology technology to develop a tool that allows accurate 
prediction of tumor peptides presented on MHC class I in the FVB mouse.   
 
Peptides that are recognized by T cells, termed T-cell epitopes, vary depending on which class I 
MHC molecule presents the peptide. Murine strains possess different class I haplotypes with 
different peptide binding preferences [6].  In mice, the class I MHC α-chain proteins are encoded 
by H-2K and H-2D.  In FVB and BALB/c mouse strains, a duplication event of the H-2D locus 
spawned the pseudogene H-2L, although the physiological relevance of this duplication remains 
unknown [7].  Because of this, we have focused our efforts on H-2K and H-2D peptide 
prediction.  The FVB strain expresses the H-2
q 
haplotype and, despite the preponderance of FVB 
mice in disease models, the MHC peptide binding motifs of the H-2
q 
molecules are understudied 
[8].  To address this paucity of data and the difficulties in studying immune responses in the FVB 
strain, we DNA sequenced the cDNA forms of H-2D
q
 and H-2K
q
 gene transcripts and 
transfected H-2D
q 
and H-2K
q
 gene constructs to facilitate high-throughput proteomic 
identification of >8500 peptides presented by MHC molecules of the H-2
q
 haplotype.  This data 
allowed us to develop an online mouse H-2 pan-specific prediction tool – that is, a prediction 
tool encompassing the H-2
b
, H-2
d
, H-2
k
, and H-2
q
 haplotypes. 
 
A pan-specific neural network method that uses pooled data from multiple MHC molecules, as 
opposed to a single allele, greatly improves predictive power and accuracy [9]. We have also 
shown that a model integrating peptide binding affinity data with eluted ligand data achieves 
highly improved predictive performance when it comes to the identification of eluted ligands and 
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T-cell epitopes [10].  Thus, the H-2D
q 
and H-2K
q
 peptide elution data were combined with 
peptide binding and eluted ligand data from other murine haplotypes (H-2
b
, H-2
d
, H-2
k
).  The 
resulting prediction tool is tailored to the “q” haplotype but allows cancer immunobiologists to 
accurately predict peptides of other murine class I haplotypes.  We named this tool “NetH2pan”, 
as an extension of our other published predictive tools (NetMHCpan).  Prior to this, NetMHCpan 
was the only murine prediction tool available for the H-2
q
 haplotype.  NetMHCpan, however, 
could only predict H-2
q 
ligands based on MHC sequence homology to other haplotypes.  
NetH2pan improves upon this tool by incorporating eluted peptide data from the H-2
q
 haplotype.  
To validate this pan-specific algorithm, we eluted >2000 H-2
q
 peptides from class I MHC on 
MMTV-PyMT primary tumor cells, identifying peptides derived from 27 cancer-associated 
source proteins.  We confirmed that the NetH2pan prediction tool successfully predicts cancer-
associated tumor peptide ligands with high fidelity (top 1%), providing a significant 
improvement to current murine peptide prediction tools.  The combined molecular, proteomic, 
and in silico MHC strategies described here empower a new generation of cancer 
immunotherapy research in murine models of breast cancer. 
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Materials & Methods 
H-2K and H-2D sequencing of the FVB strain 
High-resolution MHC typing was performed by Sequence Based Typing (SBT) at the University 
of Oklahoma Health Science Center CLIA/ASHI-accredited HLA typing laboratory on FVB 
mouse spleens.  Extracted RNA (converted to cDNA), was amplified with two pairs of primers 
specific for the 5’ and 3’ UTRs of H-2K and H-2LD loci.  H-2L and H-2D coamplification was 
dissected using locus-specific sequencing primers.  Primers and nucleotide/protein sequences 
have been deposited to GenBank (accession numbers MF352192, MF352193).   
 
Cell lines, transfection, and production of MHC complexes for elution studies 
HeLa cells were purchased from ATCC, immediately expanded, and frozen per manufacturer’s 
instructions.  721.221 cells were a kind gift from Dr. Ted Hansen (Washington University, St. 
Louis).  HeLa and 721.221 cells were authenticated by in-house HLA-typing and confirmed with 
known HLA-types of the original cells.  Cells were re-authenticated after transfection with 
soluble MHC (sMHC) constructs and prior to seeding in roller bottles.  Soluble MHC constructs 
were generated as previously described with the addition of a very low-density lipoprotein 
receptor (VLDLr) purification tag [11]. 721.221 and HeLa cells were stably transfected with the 
sMHC by nucleofection per the manufacturer’s cell-line optimized protocols (nucleofection kits 
R and V, Lonza), G418 drug selection for 10 days, and subcloned by single-cell sorting.  sMHC-
producing clones were identified using a capture enzyme-linked immunosorbent assay (ELISA) 
with anti-VLDLr (CRL-2197 hybridoma, ATCC) as the capture antibody and anti-β2-
microglobulin (DAKO) as the detection antibody, and developed with o-phenylenediamine 
dihydrochloride (Sigma). Transfected cells were seeded into 48 roller bottles and sMHC-
containing supernatant was collected. sMHC was purified from the supernatant using affinity 
on April 19, 2018. © 2018 American Association for Cancer Research. cancerimmunolres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 3, 2018; DOI: 10.1158/2326-6066.CIR-17-0298 
 7 
chromatography with an antibody to VLDLr as published [12]. Complexes were eluted from the 
column in 0.2 N acetic acid and immediately processed for isolation of the peptide ligands  
 
Liquid Chromatography-Mass Spectrometry (LC-MS) of H-2D
q
 and H-2K
q
 peptides 
Peptide ligands were eluted as described previously [1, 11].  Briefly, peptides were separated 
from purified MHC with acid boil followed by 3-kDa ultrafiltration (Merck Millipore).  Peptides 
were fractionated with reverse phase-high performance liquid chromatography (RP-HPLC) then 
analysed by LC-MS.  Nano-scale LC was performed with an Eksigent nano-LC-400 with an 
Eksigent autosampler (AB SCIEX). Fractions were combined with internal retention time (iRT, 
Biognosys) peptides before injection. Eluate was ionized with a NanoSpray III ion source (AB 
Sciex), and MS1 and MS2 fragment spectra were obtained in data dependent acquisition (DDA) 
mode using a SCIEX TripleTOF 5600.  Peptide sequences were obtained from spectra using 
PEAKS 8.0 (Bioinformatics Solutions) at a 5% FDR.  Oxidation (M,H,W), deamidation (N,Q), 
sodium adducts (D,E,C-term), acetylation (N-term), pyro-glu from Q, and cysteinylation (C) 
were used as variable modifications.  The UniProt database with Homo Sapiens or Mus Musculus 
taxonomy and iRT peptides were used as a reference library for fragments.  Identified sequences 
have been deposited to the IEDB (Submission ID 1000724, 1000726, 1000727, www.IEDB.org). 
 
Training a pan-specific murine MHC ligand prediction method 
Assembling a panel of peptide-H-2 binding and elution data 
The amino-acid sequences of the H-2D
q
 and H-2K
q
 molecules were aligned to a reference 
database of MHC sequences to determine the pseudo-sequence of MHC residues in direct 
contact with the peptide, as described in detail previously [13].  Both for H-2-D
q
 and H-2K
q
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elution data sets, potential contaminants and false positives (1-5% of the ligands) were filtered 
out using GibbsCluster [14], applying the default parameters suggested for MHC I ligands of 
variable length. Binding affinity and ligand elution data for seven additional murine MHC 
molecules (H-2D
b
, D
d
, K
b
, K
d
, K
k
, L
d
, and L
q
) were obtained from the IEDB [15], and consisted 
of 9,625 pMHC binding affinity measurements and 3,310 eluted ligands of length 8 to 11 
residues. Binding affinity values aff in IC50 nM were rescaled using the relationship t = 1-
log(aff)/log(50,000) ensuring that target values fell between 0 and 1 [16].  Because elution 
experiments only report positive peptides, negative instances must be generated artificially: for 
each H-2 molecule, the peptide length with the highest number N of observed ligands was 
determined, introducing then a flat distribution of 10*N random natural peptides for each of the 
lengths 8, 9, 10 and 11 as artificial negatives. Each training point is therefore represented by a 
triplet consisting of 1) the peptide sequence; 2) the MHC pseudo-sequence associated with the 
peptide; and 3) the target value, either as a rescaled binding affinity or as a binary value (one for 
observed ligand, zero for artificial negative).  
 
Neural network training 
A neural network ensemble was trained in 5-fold cross-validation as described [9], extending the 
architecture of the neural network with a second output neuron [10]. This addition allows 
combining heterogeneous training data by utilizing the first output neuron (and its connections 
from the hidden layer) for binding affinity examples, and the second output neuron to predict 
ligands. Because the weights between input and hidden layers are shared between the two data 
types, motifs can be learned and reinforced within and between data types. All other parameters 
were consistent with the architecture of NetMHCpan-3.0: networks were initialized with ten 
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alternative random configurations of weights, using a single hidden layer composed of either 56 
or 66 neurons and representing peptides and pseudo-sequences using BLOSUM encoding [9]. 
Up to one insertion and two deletions were allowed to accommodate peptides of lengths 8 to 11 
to a common alignment core of nine amino acids. Additional features encoded as input to the 
networks included the length of the insertion/deletion (if any) and the length of the peptide. The 
training set for H-2D
q
 included only the ligands derived from HeLa cells; ligands eluted from 
721.221 cells were reserved as an independent set to evaluate the performance of the predictor.  
 
Predictive performance was calculated in terms of Area under the ROC curve (AUC) and in 
Positive Predictive Value (PPV). In line with previous work, the predictions on the ligand data 
sets were compared against a decoy set of 999 natural random peptides for each positive 
instance, equally distributed across the four peptide lengths 8, 9, 10 and 11 [17]. For cross-
validation experiments, the partitions of positive examples were maintained unaltered, whereas 
negative examples were replaced with the 999 random decoys per positive example. The PPV 
was then calculated as the fraction of true positives among the top 0.1% ligands predicted by the 
method. 
 
Length and motif preferences of H-2 molecules 
For each MHC molecule included in the model, 400,000 random natural peptides (100,000 for 
each of the lengths 8, 9, 10, 11) were submitted to the neural networks and ranked by ligand 
prediction score. The relative frequency of each peptide length among the top 1% scoring 
peptides was then used to draw the ligand length profile characterizing each H-2 molecule. 
Similarly, the same top 1% scoring peptides were used to generated sequence motifs of the MHC 
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molecules included in the model using the software Seq2Logo [18]. For the analysis of the 
peptide cleavage preferences, ligands were mapped back to the non-redundant 
UniProtKB/Swiss-Prot database [19] to retrieve their source protein sequences. Enrichment 
scores M in the peptide flanking regions were then calculated as M=log2(Fi,A/EA), where Fi,A is 
the frequency of amino acid A at position i, and EA is the expected frequency for amino acid A 
calculated on all source proteins containing at least one ligand. 
 
Mice 
Female, five-to-eight week old FVB/NJ (Jackson Laboratories Stock Number 001800) and 
MMTV-PyMT (Jackson Laboratories Stock Number 002374) mice were purchased from Jackson 
Laboratories.  All animal work was in accordance with policies at the University of Utah, and all 
studies were approved by the University of Utah IACUC committee. MMTV-PyMT tumor cells 
were harvested from MMTV-PyMT transgenic mice, collagenase digested, and implanted into 
cleared mammary fat pads according to standard procedures [20].  Tumors were measured 
weekly and size was calculated using length and width calliper measurements in the ellipsoid 
formula (Tumor volume = 1/2(length × width
2
)).  Mice were euthanized when tumors reached a 
maximum of 2cm
3
 and tumors were flash frozen in liquid nitrogen for peptide extraction.  
 
Peptide identification from MMTV-PyMT tumors 
Anti–H-2Dq (28-14-8S hybridoma, ATCC) and anti–H-2Kq (34-1-2S hybridoma, ATCC) were 
used to generate H-2
q
 immunoaffinity columns by coupling to CNBR-activated Sepharose 4 Fast 
Flow (GE Healthcare, Sweden).  Peptides were extracted based on a previously published 
protocol (Supplementary Fig. S1) [21].  Whole tumors were flash frozen in liquid nitrogen, 
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cryogenically milled (MM400, RETSCH), suspended in lysis buffer containing octylphenoxy 
poly(ethyleneoxy)ethanol (IGEPAL) (Sigma) and cOmplete EDTA-free protease inhibitor 
cocktails (Roche), and clarified by ultracentrifugation.  Filtered lysate was passed over sequential 
anti-H-2D
q
 and H-2K
q
 columns.  Peptides were eluted in acid and boiled, isolated by RP-HPLC, 
and analysed by LC/MS using DDA mode for de novo peptide identification as described above.  
The UniProt database with Mus Musculus taxonomy was used as a reference library for 
fragments.  Peptide results can be accessed through the IEDB (Submission ID 1000724, 
http://www.iedb.org). 
 
Results 
Characterization of H-2
q
 haplotype 
We began by sequencing the class I MHC H-2
q
 loci with high-resolution MHC typing.  The 
sequencing strategy employed here amplified the regions flanked by the 5’ and 3’ UTRs for H-
2K and H-2L/D genes of the FVB/NJ strain.  Locus-specific oligonucleotide primers were used 
to separate the H-2D sequence from H-2L.  The amplification primers and nucleotide sequences 
for H-2D
q
 and H-2K
q
 have been deposited into GenBank (accession numbers MF352192, 
MF352193). The H-2L locus, although expressed in the “q” haplotype, is only present in a few 
MHC haplotypes [6], and we therefore chose to characterize only H-2D
q
 and H-2K
q
.  The 
resulting sequences for H-2
q
 loci differed by 2 and 1 amino acids from previous reports for H-
2K
q
 and H-2D
q
, respectively, a finding that is expected given strain-to-strain variation and 
improved sequencing techniques.  Having determined the sequence of H-2D
q
 and H-2K
q
, we 
proceeded to identify peptides presented by the “q” haplotype.   
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Using the MHC class I H-2K
q
 and H-2D
q 
sequences, we designed sMHC constructs that lacked 
the transmembrane domain and incorporated a VLDLr purification tag.  Engineered purification 
tags (e.g., VLDLr) eliminated the need for allele specific antibodies (28-14-8S and 34-1-2S) that 
may cross-react with other alleles within the same haplotype, allowing isolation of only the 
peptide:MHC complexes of interest.  For alleles in which the motif is not yet characterized, such 
an approach allowed the characterization of the correct motifs with high confidence. sMHC-
bound peptidomes accurately represent the full-length, membrane-bound peptidomes with 
comparable binding motifs, peptide lengths, predicted binding antigens, and putative source 
antigens [22].  Based on these findings, sMHC is a valuable and physiologically relevant tool for 
studying the immune peptidome.  Tagged, soluble forms of H-2K
q
 and H-2D
q 
were separately 
transfected into the MHC class I-negative 721.221 cell line, and high producing single-cell 
clones were obtained.  Soluble H-2D
q
 was also transfected into HeLa cells to provide additional 
unique H-2D
q
 peptides.  Multiple attempts for a high producing 721.221-H-2K
q 
were made, but 
protein expression dwindled with each expansion impeding soluble H-2K
q
 production in these 
cells.  Peptide-MHC complexes from the supernatant of high-producing clones were purified by 
anti-VLDLr immunoaffinity columns, and peptides were liberated from the MHC by boiling in 
acidic conditions.  Two-dimensional nanoLC-MS/MS yielded 8500 H-2D
q 
and 481 H-2K
q
 
different peptides, permitting the visualization of H-2D
q
 and H-2K
q
 binding motifs, ligand length 
distributions, and source protein distribution (Fig. 1).  These peptide sequences and their source 
proteins are available through the Immune Epitope Database (IEDB) (Submission IDs: 1000726 
and 1000727, http://www.iedb.org).  The high number of unique H-2D
q
 peptides was due to 
higher H-2D
q
 expression in transfected 721.221 and HeLa cells than in H-2K
q 
transfected 
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721.221 cells alone.  Physiological differences in allele expression, peptide diversity, and 
binding motifs can all contribute to fewer H-2K
q
 ligands when compared with H-2D
q
. 
 
Analysis using Seq2Logo revealed a MHC binding motif for each allele (Fig. 1A and B) [18].  
H-2D
q
 favored proline at P2 and hydrophobic residues at PΩ whereas H-2Kq favored acidic P2 
residues and a hydrophobic PΩ (Fig. 1A and B).  The ligand length preference differed 
substantially between the two loci – H-2D preferred 9-mers, whereas H-2K bound predominately 
8mers (Fig. 1C). These ligands were derived from 4000 source proteins, and most source 
proteins provided a single peptide (Fig. 1D). 
   
Generation of a prediction model for murine MHC class I 
Pooling this large set of H-2D
q
 and H-2K
q
 ligands with publicly available H-2 ligand elution and 
binding affinity data, we generated a pan-specific prediction model applicable to nine different 
mouse MHC molecules. This combination of multiple molecules and data types produced a 
consistently high performance in terms of AUC for the prediction of binding affinity (BA) and 
ligand likelihood (EL), even for alleles for which only one data type was available (Table 1). Of 
particular interest for this study, the predictor obtains a remarkably high cross-validated AUC = 
0.993 for H-2D
q
. An alternative useful performance metric is the positive predictive value (PPV), 
which measures the fraction of true positives in the top Pp % predicted ligands. Because each 
MHC molecule is expected to present approximately one out of one-thousand peptides in the 
proteome, the PPV was calculated on the top Pp = 0.1% predictions. The PPV for the five H-2 
alleles characterized by ligand data varied between 35.7% and 61.1%, with an average of 49.8% 
(Supplementary Table S1) [15, 17]. The model maintains a high predictive performance on H-
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2D
q
 ligands eluted from another cell line (721.221) that were not included in the original training 
set (AUC = 0.944, PPV = 59.7%).  Ligands detected in both the HeLa and 721.221 cell lines (see 
Supplementary Fig. S2) were excluded from this validation.  When both affinity and ligand 
elution data were available for a given allele, the combined model did not benefit from the added 
binding affinity data to predict eluted ligands, compared to a model only trained on eluted 
ligands (Table 1). However, in cases in which only binding affinity or eluted ligand data were 
available for a given allele, the combined approach had the advantage of complementing one 
data type with the other, using a single, unified model. The prediction tool can be accessed at 
http://www.cbs.dtu.dk/services/NetMHCpan-4.0/NetH2pan/. 
 
The eluted and predicted binding motifs for H-2K
q
 and H-2D
q 
both show a preference for 
hydrophobic residues in the PΩ F pocket (Fig. 1A and B; Fig. 2A and B). This hydrophobic 
amino acid preference is highly conserved amongst murine and human MHC and is essential for 
stability within the MHC class I–binding cleft [23].  The second anchor for H-2Dq is a proline at 
the P2 B pocket. The H-2K
q
 allele, on the other hand, favours peptides with acidic residues at the 
P2 anchor. The preference for acidic residues at P2 could not be captured by networks trained 
without H-2K
q
 eluted ligands. Despite the ability of pan-specific methods to infer binding motifs 
by similarity to other alleles, dissimilar molecules can be hard to predict. As a rule of thumb, the 
pan-specific method described here performed accurately for alleles with a distance D (measured 
in terms of the pseudo sequence similarity) to the training data lower than 0.1 [24]. In the 
absence of H-2K
q 
training data, the minimum distance for H-2K
q
 was D = 0.33, with H-2K
k
 
being the closest allele in the training data. This observation underscores the importance of 
collecting experimental elution data across the whole MHC sequence space.  Peptides with acidic 
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anchors have limited diversity, which might also explain the low yield of H-2K
q
 peptides in our 
experiments.  
 
An important feature of neural networks trained on peptides of variable length is their ability to 
assimilate the ligand length preferences of MHC molecules [25].  Accounting for MHC-
dependent length preferences has important implications when scanning for potential ligands in 
epitope discovery. In this respect, the model shows that H-2K
q
 has a marked preference for 8-
mers (Fig. 2C), reflecting the distribution directly observed in the elution experiments (Fig. 1C). 
This tendency is similar to the length preference for H-2K
b
, both as predicted by our model and 
as described in the literature [26]. H-2D
q
 has a more canonical peptide length distribution, 
centered on 9mers and to a lesser extent on 10mers and 11mers (Fig. 1C, 2C).  These data 
confirm that the prediction tools accurately represent the peptide dataset and that this pan-
specific approach can identify subtle differences in length and anchor preferences of the murine 
MHC Class I. 
 
Cytoplasmic proteins targeted for degradation undergo antigen processing (defined by 
proteasomal cleavage, trimming by cytosolic peptidases, and N-terminal processing by 
endoplasmic reticulum aminopeptidases).  Given this, we hypothesized that certain residues 
would be favored in the source protein regions directly surrounding the MHC presented ligands.  
Analysis of flanking source protein sequences revealed a preference for methionine (M) at N-1, 
whereas proline (P) was disfavored at both termini (N-1, C+1) (Fig. 2D). Positively charged 
residues (R, K) appeared to be enriched at C+1, C+2, whereas negatively charged residues (D, E) 
were depleted in these positions. The source proteins of H-2 ligands extracted from the IEDB 
(Fig. 2E, element-wise correlation PCC = 0.559) and in previously reported peptide cleavage 
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signatures [17] had similar patterns. To test whether these cleavability preferences could improve 
the identification of H-2 ligands, we re-trained NetH2pan including the 5-residue regions 
flanking the ligands as additional input features. We did not observe a significant impact of 
cleavability preferences in cross-validated performance, with average AUC increasing slightly 
from 0.945 (model without flanking sequences) to 0.947 (with flanks), and PPV decreasing from 
49.8% to 49.1% (Supplementary Table S2). On the H-2D
q
 evaluation set from 721.221 cells, 
AUC increased from 0.944 to 0.945, and PPV from 59.7% to 60.5%. Although signatures of 
peptide processing were found consistently across data sets and MHC alleles, their contribution 
thus did not appear to be beneficial to improving ligand prediction.  
 
Tumor antigen discovery validation of the NetH2pan algorithm 
Finally, we sought to validate the NetH2pan prediction tool on ligands directly eluted from 
primary murine tumors as a complementary method to eliminate any bias introduced by the 
sMHC approach.  The ability of NetH2pan to predict peptides presented on full length H-2D
q
 
and H-2K
q
 via physiological antigen processing would provide important validation of this tool.  
Since aberrancies to MHC class I presentation varies among tumor models, and functions as a 
mechanism of tumor immune evasion, we confirmed class I MHC expression on >60% of 
EpCAM
+
 primary tumor cells using flow cytometry (Supplementary Fig. S3).  These percentages 
correlate with global MHCI transcript expression in healthy mammary tissue and secondary 
lymphoid organs in mice [27].  Compared with splenocytes, tumor cells exhibited heterogeneous 
MHC class I protein expression (Supplementary Fig. S3E).  We next purified class I MHC from 
the five grams of murine tumors; we were able to purify >2000 H-2
q
 ligands from MMTV-PyMT 
tumors.  These findings suggest that the ability for MMTV-PyMT tumors to thrive in the FVB 
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mouse does not result from a lack of peptide presentation, but likely other T-cell-dampening 
mechanisms that require further exploration.  Therefore, neoantigen discovery paired with 
peptide prediction remains highly relevant.   
 
Peptide:MHC complexes were extracted from MMTV-PyMT tumors pooled from seven mice, 
based on a previously published protocol (Supplementary Fig. S1) [21]. Whole tumors were 
flash frozen in liquid nitrogen, cryogenically milled, and suspended in lysis buffer.  Lysates were 
clarified by ultracentrifugation and passed over sequential H-2D
q
 and H-2K
q
 columns.  Peptides 
were eluted by acid boil, and the yield of MHC was quantified by the β-2-microglobulin peak in 
first dimension HPLC (pH 2.85).  Peptides were fractionated and analyzed by LC/MS using Data 
Dependent Acquisition (H-2D
q
 and H-2K
q
) for de novo peptide identification.  Full length 
purification relied on two H-2
q
 immunoaffinity columns (28-14-8S and 34-1-2S).  Previous 
literature suggests that the 28-14-8S antibody can crossreact with both H-2D
q
 and H-2L
q
.  To 
prevent the co-elution of H-2D
q
 and H-2L
q
 peptides from undermining our analysis, we used the 
sequence available in the public domain for H-2L
q
 (GenBank AAA39573.1) and compared it to 
the sequence obtained for H-2D
q
.  We indeed find differences in the residues contained in the H-
2 peptide-binding domain. These differences suggest subtle variation in the predicted ligands of 
H-2D
q
 and H-2L
q
, allowing eluted peptides to be sorted using the Gibbs Cluster analysis.  Only 
the peptides matching the H-2D
q
 motif generated from the sMHC approach were used to validate 
NetH2pan.  Additionally, we found that 34-1-2S also recognized H-2D
q
, because LC/MS 
analysis solved H-2D
q
 peptides and H-2D
q
 heavy chains in the eluate.  Peptides eluted from 34-
1-2S columns were subjected to Gibbs Cluster analysis as well.  Because of the cross-reactivity 
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and the strict H-2K
q
 motif, 40-fold fewer H-2K
q
 peptides were identified when compared with 
H-2D
q 
(Supplementary Table S3).     
 
The list of tumor-presented peptides is accessible through IEDB, and specific MS/MS spectra are 
available upon request (Submission ID 1000724, http://www.iedb.org).  Using the H-2
q
 peptides 
extracted from PyMT tumors, two dominant motifs emerged (Fig. 3A and B) that were nearly 
identical to the sMHC eluted and predicted motifs (Figs. 1 and 2).  Of the 2000 tumor-eluted 
peptides, 27 cancer-associated source proteins were identified and used to test the prediction 
performance of NetH2pan vs. NetMHCpan-3.0 (Fig. 3C, Supplementary Table S4).  These 27 
source proteins include oncogenes, tumor suppressors, and common biomarkers, but are not 
canonical “tumor antigens”.  The spectra of three (of twenty-seven) cancer-associated peptides, 
macrophage inhibitory factor (MIF), epithelial cell adhesion molecule (EpCAM), and hepatocyte 
growth factor receptor (MET), are shown to illustrate the unambiguous proteomic data obtained 
directly from tumors (Fig. 3D–F).  The source protein sequences were subjected to NetH2pan 
and NetMHCpan-3.0 peptide predictions, then the identified eluted peptide was compared to the 
resulting predicted peptides.  Pooling all sequences of the cancer-associated proteins containing 
at least one H-2D
q
 ligand and digesting them in all possible 8- to 11-mers, resulted in a total of 
86,340 peptides. The 32 observed H-2D
q
 ligands constituted 0.04% of the total pool of 86,340 
potential ligands, a number not too distant from the 0.1% estimate assumed in earlier studies [17, 
28]. Among the top 32 ligands predicted by NetH2pan, 11 were true positives (PPV=34.4%). In 
contrast, none of the top 32 ligands predicted by NetMHCpan-3.0 were true positives.  In sum, 
NetH2pan outperformed NetMHCpan on the peptide predictions, providing improved predicted 
binding affinities (Rank scores) (Fig. 3C).  Of the 33 peptides, 32 were predicted within the top 
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3%, with the median absolute rank being 3.  In comparison, NetMHCpan predictions had a 
median absolute rank of 38.  This means that when using NetH2pan, researchers are likely to 
find the true ligands by synthesizing only 3 predicted peptides, in contrast to the 38 required 
using the earlier NetMHCpan tool.   
 
Discussion 
In summary, we sequenced the MHC class I loci of FVB mice, produced and isolated their MHC 
class I proteins, and generated an MHC class I binding motif for the FVB “q” haplotype.  Over 
8500 ligands were eluted, allowing us to design a prediction tool for antigens of interest.  This 
tool, “NetH2pan,” improves on previous “NetMHCpan” methods by utilizing both binding 
affinity and elution mouse H2 data to generate its predictions, representing a sophisticated 
peptide modelling tool for mice.  To confirm this, peptides directly identified on MMTV-PyMT 
primary tumors served as a validation of the predictive power of NetH2pan. This 
immunopeptidomics study represents the first MHC peptide characterization and prediction for 
the “q” haplotype and for MMTV-PyMT tumors. Our data also facilitates improved predictions 
of peptide presentation in other commonly used murine strains, including C57/BL6 and BALB/c. 
 
Antigen-specific T-cell responses have been difficult to study in breast cancer because the 
antigens are poorly characterized in mouse models with high penetrance of breast cancer.  Our 
goal was to enable studies of antigen-specific responses in models of spontaneous tumor 
development and metastasis, which are often on the FVB background.  Here, the identification of 
ligands directly eluted from tumors identifies MMTV-PyMT tumor-presented peptides, although 
immunogenicity studies must be undertaken to validate ligands as T-cell targets.  This approach 
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is not confined to a single antigen or murine strain, as we have provided a method improved 
from the NetMHCpan tool to predict peptides across several MHC Class I haplotypes. In this 
way, NetH2pan will be particularly useful for cancer neoepitope prediction from tumor-specific 
mutations identified via whole-exome-sequencing (WES) data in C57/BL6 tumor models, as the 
H-2
b
 predictions are now more likely to generate truly presented peptides [29].  This WES-tumor 
neoantigen-peptide prediction pipeline has been adopted and successfully used to treat human 
melanoma patients [1] .When used appropriately and in combination with WES data from 
tumors, NetH2pan can predict CD8 T-cell immune epitopes with fewer false positives.  More 
work must be done to characterize which of these peptides are unique to the tumor and capable 
of activating CTLs.  These studies are now feasible in more murine cancer models.  The 
prediction model developed in this study is publicly available online as a webserver at:  
http://www.cbs.dtu.dk/services/NetMHCpan-4.0/NetH2pan.  
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Table 1. Cross-validated performance in AUC for prediction methods trained on binding 
affinity data only (BA), eluted ligands only (EL) and a combination of both data types 
(NetH2pan). 
 
 
 
 
For binding affinity measurements, positive instances are defined as having an IC50 affinity < 500nM. For 
elution assays, the total number of data points (N) includes the positives (i.e. the observed ligands) and a 
uniform distribution of artificial negatives generated as described in Materials and Methods. This tool 
predicts two properties of each peptide; binding affinity or eluted ligand likelihood. For binding affinity 
evaluation, the binding affinity predictions were used, and for eluted ligands, the eluted ligand likelihood 
predictions. 
 
 
 
                   Binding affinity data          Eluted ligands 
Allele N Positive BA NetH2pan N Positive EL NetH2pan 
H-2D
b
 3775 730 0.943 0.945 22616 806 0.981 0.981 
H-2D
d
 413 47 0.902 0.902 0 0 NA NA 
H-2D
q
 0 0 NA NA 83107 4107 0.995 0.993 
H-2K
b
 3977 1338 0.920 0.922 21509 1774 0.936 0.933 
H-2K
d
 843 295 0.859 0.858 24148 730 0.968 0.968 
H-2K
k
 371 176 0.847 0.855 0 0 NA NA 
H-2K
q
 0 0 NA NA 8121 361 0.930 0.855 
H-2L
d
 243 50 0.939 0.951 0 0 NA NA 
H-2L
q
 3 2 NA NA 0 0 NA NA 
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Figure 1. Soluble MHC elution identifies H-2D
q
 and H-2K
q 
ligands.  A and B) Peptide binding 
motif for H-2D
q
 and H-2K
q
 (derived from the subset of 9mer and 8mer ligands, respectively). C) 
Ligand Length Distribution (normalized to the most prevalent length: 8mer for H-2K
q
, 9mer for 
H-2D
q
, D) Source protein analysis of H-2
q
 peptides (normalized to the most frequent number of 
peptides per protein). Graphs C-D were generated with 3500 721-H-2D
q
 ligands and 500 721-H-
2K
q
 ligands. 
 
Figure 2. Binding motifs predicted by the neural network model. A) H-2D
q
 shows a strong 
preference for proline at P2 and enrichment of hydrophobic/aromatic amino acids at PΩ. B) H-
2K
q
 requires acidic residues at P2 and hydrophobic amino acids at PΩ. C) Predicted ligand 
length preferences for the nine H-2 alleles included in the model, calculated from a large set of 
random natural peptides. D-E) Amino-acid enrichment in the source protein regions flanking the 
ligands, derived from soluble MHC ligands generated in this study (D) and from H-2 ligands 
extracted from the IEDB (E). Values in the heatmaps are M = log2(F/E), where F is the observed 
frequency and E the expected frequency in the source proteins containing ligands. The element-
wise correlation between the heatmaps D and E is PCC = 0.559. 
 
 
Figure 3. H-2
q
 peptides from MMTV-PyMT tumors validate prediction methods. A-B) H-2
q
 
binding motifs for peptides directly eluted from tumors, C) Comparison of predictions for 
presented cancer-associated peptides with NetMHCpan, **P = 0.0013 (binomial test), D-F) 
Select H-2D
q
 peptide MS/MS spectra of cancer-associated source proteins eluted from tumors: 
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macrophage inhibitory factor (MIF), epithelial cell adhesion molecule (EpCAM), and hepatocyte 
growth factor receptor (MET) oncogene. 
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